Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva's Huntington's Rejection May Be Neurocrine's Good Fortune

Executive Summary

Teva Pharmaceutical Industries Ltd.'s bad luck in getting its experimental Huntington's disease drug deutetrabenazine (SD-809) across the FDA's finish line may be Neurocrine Bioscience's good fortune for its investigational agent valbenazine in another indication – tardive dyskinesia, a condition for which both companies are expected to file applications for their respective products in the US.

You may also be interested in...

Neurocrine Gets First Drug For Tardive Dyskinesia To FDA

Neurocrine submits NDA for its VMAT inhibitor valbenazine for tardive dyskinesia, getting to FDA ahead of Teva, which is developing a similar product, deutetrabenazine, for the same indication.

Teva's Huntington's Pursuit Lends Insight Into Other Diseases

Teva, mostly known for being the world's largest generic company and the maker of the multiple sclerosis drug Copaxone (glatiramer acetate injection), has ventured into the rare disease area, pursuing an orphan medicine for Huntington's disease, a fatal neurodegenerative condition that affects about 30,000 Americans.

Pressure off Teva's CNS hopes as tardive dyskinesia drug succeeds

Teva's investigational drug SD-809 (deutetrabenazine) has hit its endpoint in moderate to severe tardive dyskinesia patients in a pivotal Phase II/III trial, top-line results show. The drug, which Teva acquired when it bought Auspex Pharmaceuticals earlier this year, is one of the leading candidates in this neurological disease, for which there are currently no approved treatments in the US.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts